Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

Fredsøe, Jacob; Rasmussen, Anne; Mouritzen, Peter; Bjerre, Marianne; Østergren, Peter Busch; Fode, Mikkel; Borre, Michael; Sørensen, Karina Dalsgaard

doi:10.3390/diagnostics10040188

Cited by 25 publications

(24 citation statements)

References 39 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another diagnostic miRNA panel was recently proposed by Fredsøe and colleagues [ 164 ]. The study profiled plasma samples ( n = 753) of patients affected by PCa in different stages, including BPH, localized and advanced disease, as well as control subjects.…”

Section: The Diagnostic and Prognostic Power Of Mirnas In Prostatementioning

confidence: 99%

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

Arrighetti

Beretta

2021

Pharmaceutics

View full text Add to dashboard Cite

Prostate cancer (PCa) is the fifth cause of tumor-related deaths in man worldwide. Despite the considerable improvement in the clinical management of PCa, several limitations emerged both in the screening for early diagnosis and in the medical treatment. The use of prostate-specific antigen (PSA)-based screening resulted in patients’ overtreatment and the standard therapy of patients suffering from locally advanced/metastatic tumors (e.g., radical prostatectomy, radiotherapy, and androgen deprivation therapy) showed time-limited efficacy with patients undergoing progression toward the lethal metastatic castration-resistant PCa (mCRPC). Although valuable alternative therapeutic options have been recently proposed (e.g., docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T), mCRPC remains incurable. Based on this background, there is an urgent need to identify new and more accurate prostate-specific biomarkers for PCa diagnosis and prognosis and to develop innovative medical approaches to counteract mCRPC. In this context, microRNA (miRNAs) emerged as potential biomarkers in prostate tissues and biological fluids and appeared to be promising therapeutic targets/tools for cancer therapy. Here we overview the recent literature and summarize the achievements of using miRNAs as biomarkers and therapeutic targets/tools for fighting PCa.

show abstract

Section: The Diagnostic and Prognostic Power Of Mirnas In Prostatementioning

confidence: 99%

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

Arrighetti

Beretta

2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Correlated expression levels of miR-20a, miR-21, miR-145, and miR-221 [ 186 ], miR-17, miR-20a, miR-20b, miR-106a [ 187 ] as well as miR-16, miR-148a and miR-195 [ 188 ] in the plasma could significantly distinguish high risk patients from those with low risk and some of these miRNAs were shown to confer an aggressive phenotype upon overexpression in vitro as well as an accelerated biochemical recurrence [ 187 ]. Fredsoe et al validated a blood-based miRNA diagnostic model comprising of 4 miRNAs (miR-375, miR-33a-5p, miR-16-5p and miR-409-3p), called bCaP, in 753 patients with benign prostate lesions and multiple stages of prostate cancer and showed that combined with PSA, digital rectal examination and age bCaP predicted the outcomes of biopsies better than PSA alone [ 189 ].…”

Section: Blood-based Liquid Biopsy Marker Candidatesmentioning

confidence: 99%

Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients

Balázs¹,

Antal²,

Sáfrány³

et al. 2021

JPM

View full text Add to dashboard Cite

Prostate cancer is among the most frequent cancers in men worldwide. Despite the fact that multiple therapeutic alternatives are available for its treatment, it is often discovered in an advanced stage as a metastatic disease. Prostate cancer screening is based on physical examination of prostate size and prostate-specific antigen (PSA) level in the blood as well as biopsy in suspect cases. However, these markers often fail to correctly identify the presence of cancer, or their positivity might lead to overdiagnosis and consequent overtreatment of an otherwise silent non-progressing disease. Moreover, these markers have very limited if any predictive value regarding therapy response or individual risk for therapy-related toxicities. Therefore, novel, optimally liquid biopsy-based (blood-derived) markers or marker panels are needed, which have better prognostic and predictive value than the ones currently used in the everyday routine. In this review the role of circulating tumour cells, extracellular vesicles and their microRNA content, as well as cellular and soluble immunological and inflammation- related blood markers for prostate cancer diagnosis, prognosis and prediction of therapy response is discussed. A special emphasis is placed on markers predicting response to radiotherapy and radiotherapy-related late side effects.

show abstract

“…Their levels can be modified in all stages of PCa, from incipient tumors to metastatic states. These molecules look promising but further studies for validations are needed [ 79 , 80 ].…”

Section: Other Perspectivesmentioning

confidence: 99%

PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer

Munteanu

Gulei

et al. 2020

Diagnostics

View full text Add to dashboard Cite

Prostate cancer represents the most encountered urinary malignancy in males over 50 years old, and the second most diagnosed after lung cancer globally. Digital rectal examination and prostatic specific antigen were the long-time standard tools for diagnosis but with a significant risk of overdiagnosis and overtreatment. Magnetic resonance imaging recently entered the diagnosis process, but to this date, there is no specific biomarker that accurately indicates whether to proceed with the prostate biopsy. Research in this area has gone towards this direction, and recently, serum, urine, imagistic, tissue biomarkers, and Risk Calculators promise to help better diagnose and stratify prostate cancer. In order to eliminate the comorbidities that appear along with the diagnosis and treatment of this disease, there is a constant need to implement new diagnostic strategies. Important uro-oncology associations recommend the use of novel biomarkers in the grey area of prostate cancer, to better distinguish the next step in the diagnostic process. Although it is not that simple, they should be integrated according to the clinical policies, and it should be considered that statistical significance does not always equal clinical significance. In this review, we analyzed the contribution of prostate-specific antigen (PSA)-based biomarkers (PHI, PHID, 4Kscore, STHLM3), imagistic techniques (mp-MRI and mp-US), and combined tests in the early diagnosis process of localized prostate cancer.

show abstract

Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

Cited by 25 publications

References 39 publications

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients

PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer

Contact Info

Product

Resources

About